Binding of fluvastatin to blood cells and plasma proteins
- PMID: 8229693
- DOI: 10.1002/jps.2600820914
Binding of fluvastatin to blood cells and plasma proteins
Abstract
The binding of fluvastatin, an inhibitor of hydroxymethylglutaryl coenzyme A reductase, to plasma proteins and red blood cells of rat, dog, and human in vitro was determined by ultrafiltration. Additionally, the stereospecificity of fluvastatin binding to proteins and the potential interaction between fluvastatin and the highly protein bound drugs warfarin, salicylic acid, and glyburide were investigated. Only a small fraction of fluvastatin in blood was taken up by the blood cells, amounting to 19-33% in the rat and < or = 15% in dog and humans. The plasma:blood fluvastatin ratio in these species at 37 degrees C was > or = 1.4. In human blood, this ratio was temperature independent. In the plasma concentration range 25-50,000 ng/mL, fluvastatin was > or = 98% bound to proteins. The binding was concentration dependent in the rat, but not in the dog and human. Both enantiomers of fluvastatin were > 99% bound in normal human plasma, the binding of each being unaffected by the presence of the other. A major fluvastatin-binding protein in human plasma was albumin, whereas binding to alpha 1-acid glycoprotein was relatively weak and concentration dependent. At therapeutic concentrations in normal human plasma, the protein binding of fluvastatin (0.1 microgram/mL) was unaffected by warfarin (1-10 micrograms/mL), salicylic acid (50-150 micrograms/mL), and glyburide (0.1-1 micrograms/mL). Similarly, fluvastatin had no influence on the binding of these compounds. In diluted human albumin solution (29 microM), bound fluvastatin was displaced by all three co-solutes tested.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Clinical pharmacokinetics of fluvastatin.Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003. Clin Pharmacokinet. 2001. PMID: 11368292 Review.
-
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.Am J Cardiol. 1995 Jul 13;76(2):29A-32A. doi: 10.1016/s0002-9149(05)80012-8. Am J Cardiol. 1995. PMID: 7604792 Clinical Trial.
-
Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection.J Chromatogr A. 1996 Apr 5;729(1-2):13-8. doi: 10.1016/0021-9673(95)00897-7. J Chromatogr A. 1996. PMID: 9004934
-
Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies.J Chromatogr B Biomed Sci Appl. 2001 Dec 5;765(1):81-8. doi: 10.1016/s0378-4347(01)00407-8. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11817313
-
Development and pharmacology of fluvastatin.Br J Clin Pract Suppl. 1996 Jan;77A:11-5. Br J Clin Pract Suppl. 1996. PMID: 8729584 Review.
Cited by
-
Mechanistic approaches to volume of distribution predictions: understanding the processes.Pharm Res. 2007 May;24(5):918-33. doi: 10.1007/s11095-006-9210-3. Epub 2007 Mar 20. Pharm Res. 2007. PMID: 17372687
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Clinical pharmacokinetics of fluvastatin.Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003. Clin Pharmacokinet. 2001. PMID: 11368292 Review.
-
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.Drugs. 1996 Mar;51(3):433-59. doi: 10.2165/00003495-199651030-00011. Drugs. 1996. PMID: 8882381 Review.
-
Antihyperlipidaemic agents. Drug interactions of clinical significance.Drug Saf. 1994 Nov;11(5):301-9. doi: 10.2165/00002018-199411050-00002. Drug Saf. 1994. PMID: 7873090 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources